Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27329697 | 0.88 | CYP4F2 (0.36) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL27329418 | 0.86 | PKM (0.45) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL20474689 | 0.86 | USP2 (0.37) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL28972272 | 0.82 | USP2 (0.39) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL19586263 | 0.82 | CYP4F2 (0.37) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL23390562 | 0.81 | NR1H2 (0.42) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL25591485 | 0.81 | USP2 (0.44) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL13011470 | 0.81 | USP2 (0.40) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL18497361 | 0.80 | USP2 (0.39) | USP2SMN1; SMN2NR1H2EPHX2DDB1 | |
| SCHEMBL427445 | 0.80 | USP2 (0.39) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206761-A1 | HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-06-26 | — | — | US | disclosed |
| EP-4532503-A1 | HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023232776-A1 | HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023232776-A1 | HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206761-A1 | HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2, HRAS | CYP4F2 1334/4885CYP4A11 674/4885PKM 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.